Yorktown Management & Research Company’s Tarsus Pharmaceuticals TARS Stock Holding History

Yorktown Management & Research Company’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$312K	Buy	+4,950	New	+$316K	0.19%	210

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Yorktown Management & Research Company's TARS Position: Q2 2026 in Review

Yorktown Management & Research Company opened a new position in Tarsus Pharmaceuticals (TARS) in Q2 2026: 4,950 shares worth $312K. The stake represents 0.19% of the portfolio and ranks #210 among its holdings.

93 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Yorktown Management & Research Company held 4,950 shares of Tarsus Pharmaceuticals worth $312K as of Q2 2026.
Tarsus Pharmaceuticals was a new Yorktown Management & Research Company position in Q2 2026.
Tarsus Pharmaceuticals made up 0.19% of Yorktown Management & Research Company's portfolio in Q2 2026, its #210 holding.
93 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.